Protagonist Therapeutics financials
$140.97−1.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $213.5M | $56.4M | $7.4M | $4.7M | $5.5M | $28.3M | $170.6M | $4.7M | $4.2M | $255.0M | $60.0M | $0.00 |
| Gross profit | $213.5M | $56.4M | $7.4M | $4.7M | $5.5M | $28.3M | $170.6M | $4.7M | $4.2M | $255.0M | $60.0M | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | $158.8M | -$3.6M | -$50.4M | -$46.4M | -$42.0M | -$19.3M | $126.8M | -$41.5M | -$38.8M | $206.3M | $23.0M | -$38.3M |
| Net income | $162.8M | $3.8M | -$44.4M | -$39.3M | -$34.8M | -$11.7M | $131.7M | -$33.2M | -$30.6M | $207.3M | $27.3M | -$34.1M |
| Net margin | 76.3% | 6.7% | −596.8% | −834.9% | −627.0% | −41.2% | 77.2% | −710.4% | −734.7% | 81.3% | 45.6% | — |
| Diluted EPS | $2.29 | $0.05 | $-0.69 | $-0.62 | $-0.55 | $-0.19 | $1.79 | $-0.54 | $-0.50 | $3.26 | $0.45 | $-0.58 |
| EBITDA | $158.8M | -$3.2M | -$50.0M | -$46.1M | -$42.0M | -$19.1M | $126.9M | -$41.2M | -$38.6M | $206.5M | $23.3M | -$38.1M |
| Operating cash flow | $0.00 | -$48.9M | -$37.0M | -$1.9M | $0.00 | $125.4M | -$29.2M | -$27.9M | $268.6M | -$27.4M | $17.0M | -$26.6M |
| Free cash flow | $0.00 | -$49.2M | -$37.1M | -$2.0M | $0.00 | $124.8M | -$29.5M | -$28.6M | $268.6M | -$27.7M | $16.9M | -$27.0M |
| Diluted shares | 71.0M | 70.5M | 64.0M | 63.8M | 63.5M | 63.0M | 73.6M | 61.8M | 61.3M | 63.6M | 60.5M | 59.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $420.1M | $193.7M | $128.4M | $113.7M | $168.5M | $139.7M |
| Short-term investments | $362.5M | $354.1M | $439.0M | $462.4M | $401.9M | $434.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $885.5M | $697.5M | $668.2M | $701.7M | $718.0M | $742.1M |
| Total liabilities | $44.0M | $42.0M | $53.5M | $56.3M | $50.0M | $53.1M |
| Shareholders' equity | $841.5M | $655.5M | $614.7M | $645.4M | $668.0M | $689.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology